Antitumoral and other biomedical activities of synthetic ether lysophospholipids.
Munder
P G
PG
Max-Planck-Institut für Immunobiologie, Freiburg, FRG.
Westphal
O
O
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D002462:Cell Membrane / Q000187:drug effects; D004341:Drug Evaluation; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy; D004987:Ethers / Q000138:chemical synthesis; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008244:Lysophosphatidylcholines / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D008246:Lysophospholipids / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D008262:Macrophage Activation / Q000187:drug effects; D008563:Membrane Lipids / Q000378:metabolism; D009103:Multiple Sclerosis; D009369:Neoplasms / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D004987:Ethers; D008244:Lysophosphatidylcholines; D008246:Lysophospholipids; D008563:Membrane Lipids